BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 11846211)

  • 1. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group.
    Imaizumi M; Watanabe A; Kikuta A; Takano T; Ito E; Shimizu T; Tsuchiya S; Iinuma K; Konno T; Ohi R; Hayashi Y;
    Tohoku J Exp Med; 2001 Oct; 195(2):73-83. PubMed ID: 11846211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of high-dose
    Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
    J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
    Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry. Italian Association of Pediatric Hematology-Oncology, BMT Group.
    Garaventa A; Rondelli R; Lanino E; Dallorso S; Dini G; Bonetti F; Arrighini A; Santoro N; Rossetti F; Miniero R; Andolina M; Amici A; Indolfi P; Lo Curto M; Favre C; Paolucci P; Pession A; De Bernardi B
    Bone Marrow Transplant; 1996 Jul; 18(1):125-30. PubMed ID: 8832005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies.
    Stram DO; Matthay KK; O'Leary M; Reynolds CP; Haase GM; Atkinson JB; Brodeur GM; Seeger RC
    J Clin Oncol; 1996 Sep; 14(9):2417-26. PubMed ID: 8823319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results.
    Matthay KK; O'Leary MC; Ramsay NK; Villablanca J; Reynolds CP; Atkinson JB; Haase GM; Stram DO; Seeger RC
    Eur J Cancer; 1995; 31A(4):572-5. PubMed ID: 7576971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
    Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
    Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival of children with advanced tumors by myeloablative chemotherapy and autologous peripheral blood stem cell transplantation in complete remission.
    Sato A; Imaizumi M; Saisho T; Saito T; Yoshinari M; Cui Y; Suzuki H; Koizumi Y; Ito T; Takai Y; Hayashi Y; Tamura M; Iinuma K
    Tohoku J Exp Med; 1998 Dec; 186(4):255-65. PubMed ID: 10328158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.
    Pritchard J; Cotterill SJ; Germond SM; Imeson J; de Kraker J; Jones DR
    Pediatr Blood Cancer; 2005 Apr; 44(4):348-57. PubMed ID: 15546135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11.
    Yoneda A; Shichino H; Hishiki T; Matsumoto K; Ohira M; Kamijo T; Kuroda T; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Hara J; Kaneko M; Ikeda H; Tajiri T; Mugishima H; Nakagawara A
    Pediatr Blood Cancer; 2024 Jun; 71(6):e30976. PubMed ID: 38577760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment combined with bone marrow transplantation for advanced neuroblastoma: an analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan.
    Ohnuma N; Takahashi H; Kaneko M; Uchino J; Takeda T; Iwafuchi M; Ohhira M; Nishihira H; Mugishima H; Yokoyama J
    Med Pediatr Oncol; 1995 Mar; 24(3):181-7. PubMed ID: 7838040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
    Berthold F; Boos J; Burdach S; Erttmann R; Henze G; Hermann J; Klingebiel T; Kremens B; Schilling FH; Schrappe M; Simon T; Hero B
    Lancet Oncol; 2005 Sep; 6(9):649-58. PubMed ID: 16129365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.
    Ladenstein R; Philip T; Lasset C; Hartmann O; Garaventa A; Pinkerton R; Michon J; Pritchard J; Klingebiel T; Kremens B; Pearson A; Coze C; Paolucci P; Frappaz D; Gadner H; Chauvin F
    J Clin Oncol; 1998 Mar; 16(3):953-65. PubMed ID: 9508178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation for the treatment of neuroblastoma in Korea.
    Ryu KH; Ahn HS; Koo HH; Kook H; Kim MK; Kim HK; Ghim T; Moon HN; Seo JJ; Sung KW; Shin HY; Yoo ES; Lyu CJ; Lee YH; Lee H; Cho B; Cho HS; Choi HS; Hah JO; Hwang TJ
    J Korean Med Sci; 2003 Apr; 18(2):242-7. PubMed ID: 12692423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse in the skull after myeloablative therapy for high-risk neuroblastoma.
    Sangthawan D; DesRosiers PM; Randall ME; Robertson K; Goebel S; Fallon R
    Pediatr Hematol Oncol; 2003; 20(1):23-30. PubMed ID: 12687750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
    Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
    Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
    Desai AV; Heneghan MB; Li Y; Bunin NJ; Grupp SA; Bagatell R; Seif AE
    Bone Marrow Transplant; 2016 Sep; 51(9):1204-10. PubMed ID: 27159174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma.
    Matthay KK
    Pediatr Transplant; 1999; 3 Suppl 1():72-7. PubMed ID: 10587975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
    Yalçin B; Kremer LC; Caron HN; van Dalen EC
    Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria.
    Burdach S; van Kaick B; Laws HJ; Ahrens S; Haase R; Körholz D; Pape H; Dunst J; Kahn T; Willers R; Engel B; Dirksen U; Kramm C; Nürnberger W; Heyll A; Ladenstein R; Gadner H; Jürgens H; Go el U
    Ann Oncol; 2000 Nov; 11(11):1451-62. PubMed ID: 11142486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.